Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > PRAC recommendations on signals

Adopted at the 7-10 June 2021 PRAC meeting

Philippe Calandra 16 July 2021 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021
  • Clinical trials for medicines: manage your authorisation, report safety issues – UK →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024
  • European regulation on clinical trials for medicinal products: The end of the transition period
  • The ANSM publishes its haemovigilance report for 2023
Copyright © 2018 - Pharmya - Legal terms - Quality Policy